NANOBODY FOR ALZHEIMER'S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS PHASE I CLINICAL TRIALS
(Thomson Reuters ONE) -
- Ablynx to receive ?1 million milestone payment -
GHENT, Belgium, 25 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced
that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to
the European regulatory authorities to start a Phase I clinical trial with a
Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been
developed as part of the collaboration signed between Ablynx and Boehringer and
the event triggers a ?1 million milestone payment to Ablynx.
In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research
and licensing agreement to discover and develop new therapies for Alzheimer's
disease using Ablynx's Nanobodies against a single disease target. The
collaboration has a potential value of $265 million in upfront and milestone
payments plus undisclosed royalties on product sales. Boehringer Ingelheim is
solely responsible for the development, manufacturing and commercialisation of
any products resulting from the collaboration.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented:
"We are excited that Boehringer Ingelheim has already submitted a CTA for this
Nanobody. This development candidate has the potential to be a first-in-class
therapy for Alzheimer's disease and demonstrates the power of our Nanobody
platform. We look forward to seeing this programme enter the clinic over the
coming months."
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia in adults. It is
estimated to affect 4.5 million Americans and over 30 million people worldwide
with an average course of 8-12 years. It is projected that the disease
prevalence will double over the next 20 years. Marketed products address some of
the symptoms, but there are currently no treatments available that delay or halt
the progression of the disease. Global sales of Alzheimer's disease drugs were
approximately $8 billion in 2010 and are expected to exceed $14 billion by 2015.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious and life-threatening human diseases,
including inflammation, haematology, oncology and pulmonary disease. Today, the
Company has over 25 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies, including Boehringer
Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx(at)mcomgroup.com
Complete version of the press release:
http://hugin.info/137912/R/1605625/508554.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1605625]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2012 - 02:01 Uhr
Sprache: Deutsch
News-ID 1106894
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 102 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NANOBODY FOR ALZHEIMER'S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS PHASE I CLINICAL TRIALS
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
